Louis J. Aronne

Nov 5, 2024 | healio.com | Scott Buzby |Richard Smith |Louis J. Aronne |Sean Wharton

You've successfully added Obesity in Endocrinology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Long-term tirzepatide reduced body weight and diabetes progression and was well tolerated in people with obesity and prediabetes.

Nov 1, 2024 | healio.com | Scott Buzby |Richard Smith |Louis J. Aronne

You've successfully added CHD/Prevention to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: With realization of the CV benefit of obesity treatment, GLP-1s remain in high demand and short supply.

Apr 17, 2024 | jamanetwork.com | Louis J. Aronne |Naveed Sattar |Deborah Horn |Harold Bays

Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity—Reply Effect of Tirzepatide on Maintenance of Weight Reduction Louis J. Aronne, MD; Naveed Sattar, MD; Deborah B. Horn, DO, MPH; Harold E. Bays, MD; Sean Wharton, MD; Wen-Yuan Lin, MD, PhD; Nadia N. Ahmad, MD, MPH; Shuyu Zhang, MSc; Ran Liao, PhD; Mathijs C. Bunck, MD, PhD; Irina Jouravskaya, MD, PhD; Madhumita A.

Jan 2, 2024 | digitalcommons.library.tmc.edu | Louis J. Aronne |Naveed Sattar |Deborah Horn |Harold Bays

IMPORTANCE: The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown. OBJECTIVE: To assess the effect of tirzepatide, with diet and physical activity, on the maintenance of weight reduction.

Dec 19, 2023 | healio.com | Michael Monostra |Richard Smith |Louis J. Aronne

You've successfully added Endocrinology: Obesity to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Adults who received tirzepatide for 36 weeks and then stopped therapy regained some of the weight at 88 weeks.